Search

Search Results

• 

  Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

  M. Romano, I. Pontikaki, M. Gattinara, I. Ardoino, C. Donati, P. Boracchi, P.L. Meroni, V. Gerloni

  278-285

  17-03-2014

  https://doi.org/10.4081/reumatismo.2013.682

  2631

  PDF: 1360
• 

  Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE)

  G. Carlino, M. Fornaro, L. Santo, R. Bucci, A. Semeraro, L. Quarta, F. D'Onofrio, A. Marsico, C. Zuccaro, P.C. Falappone, D. Mazzotta, F.P. Cantatore, M. Muratore, F. Iannone

  24-30

  01-04-2019

  https://doi.org/10.4081/reumatismo.2019.1154

  1550

  PDF: 1062

• Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort

  E. Molteni, C. Pirone, F. Ceccarelli, C. Castellani, C. Alessandri, M. Di Franco, V. Riccieri, F.R. Spinelli, R. Priori, R. Scrivo, F. Conti

  24-06-2024

  https://doi.org/10.4081/reumatismo.2024.1608

  1458

  PDF: 531
• 

  Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

  C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco

  19-12-2023

  https://doi.org/10.4081/reumatismo.2023.1602

  1784

  PDF: 429
• 

  Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

  M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli, R. Caporali

  17-07-2023

  https://doi.org/10.4081/reumatismo.2023.1544

  999

  PDF: 541
• 

  Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

  G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini, A. Fassio

  08-05-2023

  https://doi.org/10.4081/reumatismo.2023.1559

  1580

  PDF: 872

• Long-term survival of methotrexate in psoriatic arthritis

  M. Ricci, G. De Marco, F. Desiati, D. Mazzocchi, L. Rotunno, N. Battafarano, A. Marchesoni

  125-131

  https://doi.org/10.4081/reumatismo.2009.125

  1190

  PDF: 879

• Biologic therapy with anti-TNFa in rheumathoid atrhritis

  G. Ferraccioli

  17-21

  https://doi.org/10.4081/reumatismo.2005.4s.17

  743

  PDF: 673

• The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis

  M. Varenna, D. Gatti

  163-171

  https://doi.org/10.4081/reumatismo.2010.163

  1752

  PDF: 1181